7 active not recruiting, 5 recruiting, 2 unknown, 1 completed. 11 Phase 2, 7 Phase 1, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Active not recruiting 6, Recruiting 4, Withdrawn 1 |
| Phase 1 | 7 | Recruiting 3, Active not recruiting 2, Completed 1, Not yet recruiting 1 |
| Phase 3 | 4 | Active not recruiting 2, Unknown 2 |
Follow High Grade B-Cell Lymphoma, Not Otherwise Specified: new trials by email Literature Review of High Grade B-Cell Lymphoma, Not Otherwise Specified trials Research Report on High Grade B-Cell Lymphoma, Not Otherwise Specified
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study") Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - AIDS-Related Diffuse Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 | Not yet recruiting | National Cancer Institute (NCI) | 15 | 2026-10-09 | 2026-08-13 |
| Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - B-Cell Non-Hodgkin Lymphoma, Burkitt Lymphoma | Phase 2 | Recruiting | University of Washington | 18 | 2025-12-07 | 2026-10-21 |
| SynKIR-310 for Relapsed/Refractory B-NHL SynKIR-310 - B Cell Lymphoma, NHL, Adult | Phase 1 | Recruiting | Verismo Therapeutics | 36 | 2024-11-01 | 2026-04-14 |
| Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL Epcoritamab - DLBCL - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | Phase 2 | Recruiting | Australasian Leukaemia and Lymphoma Group | 39 | 2023-12-11 | 2024-07-22 |
| A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies IDP-121 - Multiple Myeloma (MM), Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 / Phase 2 | Recruiting | IDP Discovery Pharma S.L. | 37 | 2023-06-05 | 2025-05-01 |
| Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma Chimeric Antigen Receptor T-Cell Therapy, Quality-of-Life Assessment, Questionnaire Administration - Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 2 | Active not recruiting | Northwestern University | 24 | 2022-03-21 | 2024-10-16 |
| Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma Biospecimen Collection, Computed Tomography, Cyclophosphamide - Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 422 | 2021-05-20 | 2026-10-01 |
| Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma Orelabrutinib+R-CHOP; Orelabrutinib+R-DA-EPOCH; Orelabrutinib+R-HD MTX;Orelabrutinib+R+other chemotherapies - High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified | Phase 3 | Unknown | Shandong Provincial Hospital | 130 | 2021-04-15 | 2021-11-19 |
| Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma Zanubrutinib+R-CHOP; Zanubrutinib+R-DA-EPOCH; Zanubrutinib+R-HD MTX, R-CHOP; R-DA-EPOCH; R-HD MTX - High Grade B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements | Phase 3 | Unknown | Shandong Provincial Hospital | 160 | 2021-03-01 | 2021-12-21 |
| Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma Polatuzumab Vedotin, Rituximab, Prednisone - Aggressive Non-Hodgkin Lymphoma, ALK-Positive Large B-Cell Lymphoma | Phase 1 / Phase 2 | Active not recruiting | University of Washington | 56 | 2020-10-27 | 2026-10-02 |
| Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Bortezomib, Rituximab, Venetoclax - High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Burkitt Lymphoma | Phase 2 | Withdrawn | Rutgers, The State University of New Jersey | 2020-05-06 | 2026-01-30 | |
| Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 363 | 2019-10-22 | 2026-10-26 |
| Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma Cyclophosphamide, Doxorubicin Hydrochloride, Prednisone - Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type | Phase 1 | Completed | Northwestern University | 12 | 2019-03-13 | 2025-06-18 |
| Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide - Aggressive Non-Hodgkin Lymphoma, Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma | Phase 2 | Active not recruiting | David Bond, MD | 30 | 2019-01-02 | 2026-02-06 |
| Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas Nivolumab, Varlilumab - ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 54 | 2018-12-21 | 2026-10-26 |
| Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes, Bendamustine Hydrochloride, Cyclophosphamide - B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, B-Cell Prolymphocytic Leukemia | Phase 1 | Active not recruiting | City of Hope Medical Center | 37 | 2014-10-14 | 2026-10-26 |
| Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia Blinatumomab, Cyclophosphamide, Cytarabine - B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 276 | 2011-08-26 | 2026-07-15 |
Lymphoma, Large B-Cell, Diffuse (15) · Burkitt Lymphoma (5) · Lymphoma, B-Cell (5) · Lymphoma, Mantle-Cell (4) · Lymphoma, B-Cell, Marginal Zone (3) · Lymphoma, Follicular (3) · Dendritic Cell Sarcoma, Interdigitating (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma, Primary Effusion (2) · Plasmablastic Lymphoma (2) · Leukemia, Hairy Cell (1) · Leukemia, Prolymphocytic, B-Cell (1) · Lymphoma, Non-Hodgkin (1) · Lymphomatoid Granulomatosis (1) · Multiple Myeloma (1)
Hemic and Lymphatic Diseases (17) · Immune System Diseases (17) · Immunoproliferative Disorders (17) · Lymphatic Diseases (17) · Lymphoma (17) · Lymphoproliferative Disorders (17) · Neoplasms (17) · Neoplasms by Histologic Type (17) · Lymphoma, Non-Hodgkin (16) · Lymphoma, B-Cell (11) · DNA Virus Infections (5) · Epstein-Barr Virus Infections (5) · Herpesviridae Infections (5) · Infections (5) · Tumor Virus Infections (5)
Cyclophosphamide (9) · Rituximab (9) · Prednisone (8) · CT-P10 (7) · Doxorubicin (7) · deltacortene (7) · Vincristine (6) · prednylidene (6) · Etoposide (5) · Magnetic Resonance Spectroscopy (4) · Specimen Handling (4) · Biopsy (3) · Nivolumab (2) · glofitamab (2) · venetoclax (2)
National Cancer Institute (NCI) (4) · Northwestern University (2) · Shandong Provincial Hospital (2) · University of Washington (2) · Australasian Leukaemia and Lymphoma Group (1) · City of Hope Medical Center (1) · David Bond, MD (1) · IDP Discovery Pharma S.L. (1) · M.D. Anderson Cancer Center (1) · Rutgers, The State University of New Jersey (1) · Verismo Therapeutics (1)
United States (12) · China (2) · Australia (1) · Spain (1)
Xin Wang, PhD (2) · David A Bond, MD (1) · Elias Jabbour, MD (1) · Elizabeth A Brem (1) · Enrique Ocio San Miguel, MD, PhD (1) · Jeremy S Abramson (1) · Laura A Johnson, PhD (1) · Mengyang Di, MD, PhD (1) · Rajat Bannerji (1) · Reem Karmali (1) · Reem Karmali, MD (1) · Ryan Lynch (1) · Stefan K Barta (1) · Stephen M Ansell (1) · Tanya Siddiqi (1)
PMID 28859185, PMID 29352703, PMID 34492703, PMID 34634256, PMID 34686472, PMID 35622074, PMID 36521030, PMID 37131217, PMID 37187201, PMID 38551807, PMID 40802906, PMID 41671463, PMID 42660130
P30CA060553 (2), P30CA033572 (1), P30CA072720 (1), U10CA180821 (1), U10CA180888 (1), UM1CA121947 (1), UM1CA186686 (1), UM1CA186709 (1)